Nektar Therapeutics/$NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Ticker
$NKTR
Sector
Primary listing
Employees
63
Headquarters
Website
NKTR Metrics
BasicAdvanced
$2.1B
-
-$9.73
1.23
-
Price and volume
Market cap
$2.1B
Beta
1.23
52-week high
$78.81
52-week low
$7.99
Average daily volume
954K
Financial strength
Current ratio
4.974
Quick ratio
4.59
Long term debt to equity
142.948
Total debt to equity
165.763
Interest coverage (TTM)
-4.99%
Profitability
EBITDA (TTM)
-129.745
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-297.07%
Operating margin (TTM)
-236.77%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-27.98%
Return on equity (TTM)
-217.94%
Valuation
Price to revenue (TTM)
22.824
Price to book
16.88
Price to tangible book (TTM)
16.95
Price to free cash flow (TTM)
-6.021
Free cash flow yield (TTM)
-16.61%
Free cash flow per share (TTM)
-12.411
Growth
Revenue change (TTM)
-43.89%
Earnings per share change (TTM)
12.14%
3-year revenue growth (CAGR)
-15.66%
10-year revenue growth (CAGR)
-13.32%
3-year earnings per share growth (CAGR)
-30.95%
10-year earnings per share growth (CAGR)
0.56%
NKTR News
AllArticlesVideos
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
Newsfile Corp·21 hours ago
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Newsfile Corp·1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
Newsfile Corp·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $2.1B as of April 07, 2026.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of April 07, 2026.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of April 07, 2026.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.